| Literature DB >> 17029623 |
Abstract
BACKGROUND: The potential public health benefits of targeting environmental interventions by genotype depend on the environmental and genetic contributions to the variance of common diseases, and the magnitude of any gene-environment interaction. In the absence of prior knowledge of all risk factors, twin, family and environmental data may help to define the potential limits of these benefits in a given population. However, a general methodology to analyze twin data is required because of the potential importance of gene-gene interactions (epistasis), gene-environment interactions, and conditions that break the 'equal environments' assumption for monozygotic and dizygotic twins.Entities:
Mesh:
Year: 2006 PMID: 17029623 PMCID: PMC1629012 DOI: 10.1186/1742-4682-3-35
Source DB: PubMed Journal: Theor Biol Med Model ISSN: 1742-4682 Impact factor: 2.432
Figure 1The four-category model. A population divided into: (a) high and low genotypic risk categories (rg and rog); (b) high and low environmental risk categories (re and roe); (c) four categories based on combined genotypic and environmental risk.
The four category model: risks and cases for a population of size N.
| Rge | γεN | γε RgeN | |
| Rgo | γ (1-ε)N | γ (1-ε)RgoN | |
| Roe | ε (1-γ)N | ε (1-γ)RoeN | |
| Roo | (1-ε) (1-γ)N | (1-ε) (1-γ)RooN | |
| N | rtN | ||
Constraints on model parameters
Further constraints on model parameters
| If | ||
Limits on the gene-environment interaction factor (fge) and the proportion of the population in the high-genotypic risk group (γ).
| Genetic effect in high-exposure group only | 1/PAFEe | Positive | γmaxge (where PAFEge = PAFEe; PI = 1; and Uge = 1-γ). | γminge (where Rge = 1). | ||
| Multiplicative | 1 | γmaxge = γ0 (where PAFEge = PAFEe; R00 = 0; and PAFGg = 1). | ||||
| Additive | 0 | Zero | γ0 (where R00 = 0). | |||
| Reverse multiplicative | -rt/(1-rt) | Negative | γneg = γminge (where PAFEge = 0 and Rge = 1) | |||
| Genetic effect in low-exposure group only | -ε/(1-ε)PAFEe | γneg (where PAFEge = 0 and PI = 0). | ||||
Special cases with γmax = γminfor Uge ≥ 0
| 1 | 1 | rt = 1 PAFe = 0 | Undefined (PAFge = 0) | ||||||||
| R00 | 1 | γminge = γmaxge (Rge = 1 and PAFge = PAFe) fge = 1/PAFe | PI = 1 Uge = 1-γ | 1 | 1 | ||||||
| Rg0 | 1 | γminge = γmaxge (Rge = 1 and PAFge = PAFe) fge ≥ 1 | PI = 1 Uge = 1-γ | R00 | R00 | 0 | 1 | rt = γε PAFe = 1 | PI = 1 Uge = 1-γ | ||
| R00 | R00 | Rg0 | 1 | γminge = γ0 = γmaxge (Rge = 1; R00 = 0; PAFge = PAFe) fge = 1 | PI = 1 Uge = 1-γ | 0 | 0 | ||||
| Rg0 | 1 | γminge = γ0 (Rge = 1; R00 = 0) 0 ≤ fge ≤ 1 | 0 = PI = 1 Uge = PI-γ | 0 | 0 | 1 | 1 | rt = γ PAFe = 0 | Undefined (PAFge = 0) | ||
| 0 | R0e | 1-R0e | 1 | γminge = γ0 (Rge = 1; R00 = 0) fge = 0 | PI = γ Uge = 0 | 0 | 0 | ||||
| 0 | R0e | 0 | 1 | rt = ε PAFe = 1 | PI = γ Uge = 0 | ||||||
| 0 | 1 | ||||||||||
Comparison with classical twin study
| Additive and dominance terms only: VDZg = 1/2VA+1/4VD | Variable: VDZg = pDZgVg with 0 < = pDZg < = 1/2 | |
| Equal environments assumption: cMD = 1 | Variable: 1 < = cMD < = RMD cMD = RMD implies Vg = 0 | |
| Siblings not included. | Variable: 0 < = cSD < = RSD Familial aggregation may be due to genes (cSD = 0) or environment (cSD = RSD). | |
| None | Variable: Vge = f2ge· Vg· Ve/r2t -ε/(1-ε)PAFe < = fge < = 1/PAFe | |
| None | None | |
| Total phenoptypic variance given by: VP = Vg+Ve VP is input and a single solution for Ve and Vg calculated. Heritabilities are given by: H2 = Vg/VP h2 = VA/VP | Ve and ε are input and Vg and Vge calculated, for a chosen cMD and all possible values of fge and pDZg. Method is not valid if RSD = 1. | |
Figure 2Example model solution space with R. Input parameters: λMZ = 3.4, λDZ = 3, λsib = 2, ε = 0.2, PAFEe = 0.5, cMD = 1, rt = 0.1. Hence RMD = 1.2, RSD = 0.5.
Figure 3Example model solution space with R. Input parameters as for Figure 2.
Figure 4Example full model solution space with R. Input parameters as for Figure 2, with the solution space transformed so that fge is on the horizontal axis.
Input variables
| Breast cancer | 4.09 | 2.51 | 2.01 | 0.62 | 0.15 | 0.036 |
| Lung cancer | 6.27 | 6.14 | 3.16 | 0.15 | 0.86 | 0.017 |
| Schizophrenia | 52.1 | 14.2 | 8.6 | 0.62 | 0.15 | 0.01 |
| 0.15 | 0.86 | |||||